Bluebird Bio Files US Application For β-thalassemia Gene Therapy

Loading...
Loading...
  • Bluebird Bio Inc BLUE completed the rolling submission of its marketing application to the FDA seeking approval for betibeglogene autotemcel (beti-cel) gene therapy.
  • The application covers adult, adolescent, and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions across all genotypes. 
  • Read Next: Bluebird Bio's Shares Drop To 52-Week Low After Another Gene Therapy Trial Placed On FDA Hold.
  • The FDA previously granted beti-cel Orphan Drug status and Breakthrough Therapy designation for transfusion-dependent β-thalassemia (TDT). 
  • If approved, beti-cel will be the first hematopoietic (blood) stem cell (HSC) ex-vivo gene therapy for patients in the U.S.
  • The submission is based on data from Phase 3 HGB-207 (Northstar-2) and HGB-212 (Northstar-3) studies and the Phase 1/2 HGB-204 (Northstar) and HGB-205 studies. 
  • Together, these studies represent more than 220 patient-years of experience with beti-cel.
  • The data include two patients with up to seven years of follow-up, eight with at least six years of follow-up, and 19 with at least five years of follow-up.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: BLUE stock gained 5.61% at $19 in premarket trading on the last check Wednesday.
Posted In: BiotechNewsHealth CareSmall CapFDAMoversTrading IdeasGeneralbeta-thalassemiaBriefsgene therapy
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...